Andrew Elnatan
Senior VP of Regulatory Affairs, CMC & QualityMr. Andrew Elnatan was VP and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls & Quality of SELLAS Life Sciences Group, Inc. from January 2023 until 2025 and serves as its Senior VP of Regulatory Affairs, CMC & Quality since 2025. He has extensive regulatory and CMC pharmaceutical industry experience in the areas of oncology, immunology and hematological diseases. His career spans over many years at companies such as Amgen, SQZ Biotechnologies Company, International AIDS Vaccine Initiative and Celldex Therapeutics. He has successfully coordinated regulatory submissions, negotiations and approvals of drugs and biologics with several global regulatory bodies, including the US Food and Drug Administration (FDA), Chinas National Medical Products Administration Center for Drug Evaluation, Taiwan Food and Drug Administration, Australian Therapeutic Goods Administration and the European Medicines Agency and other EU national agencies. This includes achievement of US FDA Breakthrough Therapy Designation granted for an oncology asset.
Positions
- Company NameSELLAS Life Sciences Group, Inc.Stock CodeSLSPositionSenior VP of Regulatory Affairs, CMC & QualityColleagues
- AMAngelos M. StergiouFounder, President, CEO & Director
- JWJohn W. VarianIndependent Chairman of Board
- JTJohn Thomas BurnsSenior VP & CFO
- DCDragan CicicSenior VP & Chief Development Officer
- SEStacy E. YeungVP, General Counsel & Corporate Secretary
- JWJane WasmanIndependent Director
- RLRobert L. Van NostrandIndependent Director
- KBKatherine Bach KalinIndependent Director
